Maastricht University Details Findings in Contraceptives (Status of Emergency Contraceptives in Europe One Year after the European Medicines Agency's…

Maastricht University Details Findings in Contraceptives (Status of Emergency Contraceptives in Europe One Year after the European Medicines Agency’s Recommendation to Switch Ulipristal Acetate to Non-Prescription Status)By a News Reporter-Staff News Editor at Biotech Week — Current study results on Drugs and Therapies – Contraceptives have been published. According to news reporting out of Maastricht, Netherlands, by NewsRx editors, research stated, “In November 2014, the European Medicines Agency (EMA) recommended switching the emergency contraceptive (EMC) ulipristal acetate to non-prescription status. This study’s objective is to assess the current legal status of the two EMCs ulipristal acetate and levonorgestrel in Europe and to report on the development of sales figures for EMCs since they were made freely available.”Our news journalists obtained a quote from the research from Maastricht University, “Health authorities were contacted in autumn 2015 and asked about the current status of EMCs and whether the sales figures had changed after a switch to non-prescription status. Additionally, data on consumption were collected in 18 German community pharmacies. As of November 2015, most countries in the European Union (EU) have followed the EMA recommendation. Hungary kept the prescription-only status. In Malta, EMC drugs are not authorized. Germany and Croatia switched levonorgestrel to non-prescription status as well. Of the EU candidate and European Free Trade Association countries, ulipristal acetate is available without prescription in Norway and Bosnia and Herzegovina only. Several countries reported an increase in EMC sales since the switch. An EMA recommendation can strongly contribute to the harmonization of a drug’s legal status in the EU.”According to the news editors, the research concluded: “In most European countries, ulipristal acetate and/or levonorgestrel are now freely available.”For more information on this research see: Status of Emergency Contraceptives in Europe One Year after the European Medicines Agency’s Recommendation to Switch Ulipristal Acetate to Non-Prescription Status. Public Health Genomics, 2016;19(4):203-210. Public Health Genomics can be contacted at: Karger, Allschwilerstrasse 10, Ch-4009 Basel, Switzerland. (Karger – www.karger.com/; Public Health Genomics – content.karger.com/ProdukteDB/produkte.asp?Aktion=JournalHome&ProduktNr=224224)Our news journalists report that additional information may be obtained by contacting University, Fac Hlth Med & Life Sci, Sch Public Hlth & Primary Care CAPHRI, Dept. of Int Hlth, Maastricht, Netherlands (see also Drugs and Therapies – Contraceptives).Keywords for this news article include: Maastricht, Netherlands, Europe, Levonorgestrel Therapy, Drugs and Therapies, Pharmaceuticals, Contraceptives, Sex Hormones, Progestins, Maastricht University.Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2016, NewsRx LLC(c) 2016 NewsRx LLC, source Health Newsletters

Leave a Reply